{'fraction_non_alphanumeric': 0.03024193548387097, 'fraction_numerical': 0.0010080645161290322, 'mean_word_length': 5.895833333333333, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
[Mechanism of action of platelet aggregation inhibitors].

The antiaggregant drugs class is registering in the last few years an increased dynamics. The action mechanism relies either on the platelet activator pathway inhibition, or on the natural inhibitory pathway stimulation. The most frequently implied action mechanisms are COX inhibition, the cyclic nucleotides synthesis inhibition, ADP receptor's inhibition, TxA2 synthesis/action's inhibition, the fibrinogen receptor's blocking. The foreseen introduction of new antiaggregant drugs does have in view the von Willebrand factor-GP I interaction's inhibition, NO releasing, the platelet activation's inhibition using thrombin, the collagen--platelet interaction's inhibition. The widening of this drugs class, established by the constant creation of new antiaggregants, is leading to a doubtless result, meaning the prognosis improvement of certain diseases, in which the platelet activation is a key link of the pathogenic mechanism.